EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Angelo Ruggiero iD, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio iD, Lucia Gallo, Matteo Megna

Clinical, Cosmetic and Investigational Dermatology · 2023-02 · Volume 16 · 529-536

DOI: 10.2147/ccid.s402183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2023-02. Verfasst von Angelo Ruggiero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

anti-IL-23biologicsguselkumabpsoriasisreal-world practicerisankizumabtildrakizumab

Autor:innen und Institutionen

  • Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

ORCID-Profile: Angelo Ruggiero, Luca Potestio

Zitieren

APA

Ruggiero, A., Fabbrocicni, G., Cacciapuoti, S., Potestio, L., Gallo, L., & Megna, M. (2023). Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, Cosmetic and Investigational Dermatology, Volume 16, 529-536. https://doi.org/10.2147/ccid.s402183

Vancouver

Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, Cosmetic and Investigational Dermatology. 2023;Volume 16:529-536. doi:10.2147/ccid.s402183

BibTeX
@article{Ruggiero2023,
  author = {Ruggiero, Angelo and Fabbrocicni, Gabriella and Cacciapuoti, Sara and Potestio, Luca and Gallo, Lucia and Megna, Matteo},
  title = {Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study},
  journal = {Clinical, Cosmetic and Investigational Dermatology},
  year = {2023},
  volume = {Volume 16},
  pages = {529--536},
  doi = {10.2147/ccid.s402183}
}
Kostenlos starten →